Wednesday’s comparative research, the primary of its type, confirmed that Eli Lilly’s tirzepatide achieved 47% higher weight reduction over 72 weeks than Novo Nordisk’s semaglutide.
发布者:BY CHRISTOPHER DUE KARLSSON,转转请注明出处:https://robotalks.cn/novo-nordisk-on-lillys-new-weight-loss-study-we-have-yet-to-see-complete-data/